Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA binding motif protein 23 (RBM23) is a member of the U2AF-like family of RNA binding proteins that functions as both a transcription coactivator and a pre-mRNA splicing factor[1][3][6]. RBM23 interacts with steroid nuclear receptors, localizes to promoters of steroid-responsive genes, and increases transcription of steroid-responsive reporters in a hormone-dependent manner[1][6]. It is implicated in steroid receptor-dependent regulation of alternative splicing and contains multiple RNA recognition motifs (RRMs) important for binding mRNA and interaction with spliceosomal components. Multiple transcript variants encode different isoforms of this protein; it is expressed in many tissues and has been detected in various human cancers, with some data suggesting potential prognostic significance[1][5]. No specific drugs or biomarkers are currently established for RBM23, and it is not considered a direct therapeutic target, but it may be relevant for studies of gene regulation, alternative splicing, and cancer biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA binding motif protein 23 (RBM23).